Vaxcyte CMO reports options on 23,941 shares

Chief Medical Officer Luis Jodar reports an initial option holding for 23,941 Vaxcyte shares vesting monthly over three years from May 22, 2026.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported the initial equity holdings of Chief Medical Officer Luis Jodar on a Form 3. The filing shows a stock option to purchase 23,941 shares of common stock at an exercise price of $47.30 per share, expiring on May 22, 2036.

According to the disclosure, these options vest monthly over 36 months starting from May 22, 2026, contingent on Dr. Jodar’s continuous service with the company through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jodar Luis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) F1	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 23,941 contracts (Direct)

Footnotes (1)

1. F1. Options vest monthly over 36 months from May 22, 2026, the grant date, subject to Reporting Person's continuous service to the Company through each such date.

Key Figures

Underlying common shares: 23,941 shares Exercise price: $47.30 per share Vesting period: 36 months +2 more

5 metrics

Underlying common shares 23,941 shares Shares underlying the reported stock option held directly by the Chief Medical Officer

Exercise price $47.30 per share Exercise price of the reported stock option for Vaxcyte common stock

Vesting period 36 months Options vest monthly over 36 months from the May 22, 2026 grant date

Expiration date May 22, 2036 Expiration date of the reported stock option

Post-report option holding 23,941 options Total stock options reported as held directly following the Form 3 entry

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Stock Option (right to buy) financial

"The filing shows a stock option (right to buy) to purchase 23,941 shares"

exercise price financial

"an exercise price of $47.30 per share applies to the stock option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Options vest monthly over 36 months from May 22, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"the option has an expiration date of May 22, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Vaxcyte (PCVX) report for Chief Medical Officer Luis Jodar?

Vaxcyte reported that Chief Medical Officer Luis Jodar holds a stock option to purchase 23,941 shares of common stock, as disclosed in his Form 3 initial statement of beneficial ownership.

What is the exercise price of Luis Jodar’s reported stock options in PCVX?

The reported stock option for Chief Medical Officer Luis Jodar has an exercise price of $47.30 per share, giving him the right to buy Vaxcyte common stock at that price, subject to vesting and expiration terms.

When do the Vaxcyte (PCVX) stock options reported by Luis Jodar start vesting?

The stock options reported by Luis Jodar vest monthly over 36 months beginning on May 22, 2026. Each monthly vesting is contingent on his continuous service with Vaxcyte through the relevant vesting date.

When do Chief Medical Officer Luis Jodar’s Vaxcyte (PCVX) stock options expire?

The disclosed stock options held by Chief Medical Officer Luis Jodar expire on May 22, 2036. After that date, any unexercised portion of the option can no longer be used to purchase Vaxcyte common stock.

How many underlying Vaxcyte (PCVX) shares are covered by Luis Jodar’s reported stock option?

The reported stock option held by Chief Medical Officer Luis Jodar covers 23,941 underlying shares of Vaxcyte common stock, all held as a direct ownership position according to the Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:33 PM Accepted by SEC EDGAR 09/09/2026 - 05:33 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jodar Luis

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/31/2026

3. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	05/22/2036	Common Stock	23,941	$47.3	D

Explanation of Responses:

1. Options vest monthly over 36 months from May 22, 2026, the grant date, subject to Reporting Person's continuous service to the Company through each such date.

Remarks:

	Luis Jodar, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)